Dartmouth College

Dartmouth Digital Commons
Dartmouth Scholarship

Faculty Work

2-5-2013

Development of a Diagnostic Test Set to Assess Agreement in
Breast Pathology: Practical Application of the Guidelines for
Reporting Reliability and Agreement Studies (GRRAS)
Natalia V. Oster
University of Washington

Patricia A. Carney
Oregon Health and Science University

Kimberly H. Allison
Stanford University

Donald L. Weaver
University of Vermont

Lisa Reisch
University of Washington

See
next
page
additional
authors
Follow
this
andfor
additional
works
at: https://digitalcommons.dartmouth.edu/facoa
Part of the Medical Pathology Commons, Neoplasms Commons, and the Women's Health Commons

Dartmouth Digital Commons Citation
Oster, Natalia V.; Carney, Patricia A.; Allison, Kimberly H.; Weaver, Donald L.; Reisch, Lisa; Longton, Gary;
and Onega, Tracy, "Development of a Diagnostic Test Set to Assess Agreement in Breast Pathology:
Practical Application of the Guidelines for Reporting Reliability and Agreement Studies (GRRAS)" (2013).
Dartmouth Scholarship. 1269.
https://digitalcommons.dartmouth.edu/facoa/1269

This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has
been accepted for inclusion in Dartmouth Scholarship by an authorized administrator of Dartmouth Digital
Commons. For more information, please contact dartmouthdigitalcommons@groups.dartmouth.edu.

Authors
Natalia V. Oster, Patricia A. Carney, Kimberly H. Allison, Donald L. Weaver, Lisa Reisch, Gary Longton, and
Tracy Onega

This article is available at Dartmouth Digital Commons: https://digitalcommons.dartmouth.edu/facoa/1269

Oster et al. BMC Women's Health 2013, 13:3
http://www.biomedcentral.com/1472-6874/13/3

RESEARCH ARTICLE

Open Access

Development of a diagnostic test set to assess
agreement in breast pathology: practical
application of the Guidelines for Reporting
Reliability and Agreement Studies (GRRAS)
Natalia V Oster1*, Patricia A Carney2, Kimberly H Allison3, Donald L Weaver4, Lisa M Reisch1, Gary Longton5,
Tracy Onega6, Margaret Pepe5, Berta M Geller7, Heidi D Nelson8, Tyler R Ross1, Anna N A Tosteson6
and Joann G Elmore1

Abstract
Background: Diagnostic test sets are a valuable research tool that contributes importantly to the validity and
reliability of studies that assess agreement in breast pathology. In order to fully understand the strengths and
weaknesses of any agreement and reliability study, however, the methods should be fully reported. In this paper
we provide a step-by-step description of the methods used to create four complex test sets for a study of
diagnostic agreement among pathologists interpreting breast biopsy specimens. We use the newly developed
Guidelines for Reporting Reliability and Agreement Studies (GRRAS) as a basis to report these methods.
Methods: Breast tissue biopsies were selected from the National Cancer Institute-funded Breast Cancer Surveillance
Consortium sites. We used a random sampling stratified according to woman’s age (40–49 vs. ≥50), parenchymal
breast density (low vs. high) and interpretation of the original pathologist. A 3-member panel of expert breast
pathologists first independently interpreted each case using five primary diagnostic categories (non-proliferative
changes, proliferative changes without atypia, atypical ductal hyperplasia, ductal carcinoma in situ, and invasive
carcinoma). When the experts did not unanimously agree on a case diagnosis a modified Delphi method was used
to determine the reference standard consensus diagnosis. The final test cases were stratified and randomly assigned
into one of four unique test sets.
Conclusions: We found GRRAS recommendations to be very useful in reporting diagnostic test set development
and recommend inclusion of two additional criteria: 1) characterizing the study population and 2) describing the
methods for reference diagnosis, when applicable.
Keywords: Reporting guidelines, Reliability of results, Agreement studies, Breast, Pathology, Diagnostic techniques

Background
In 2011, the Guidelines for Reporting Reliability and
Agreement Studies (GRRAS) were developed to outline
and describe key methodological issues that should be
addressed when reporting on reliability and agreement
studies [1]. Clinicians’ interpretive reliability and diagnostic agreement are often evaluated using test sets. Yet,
the methods used to develop these test sets are complex
* Correspondence: nvoster@uw.edu
1
Department of Medicine, University of Washington, Seattle, WA, USA
Full list of author information is available at the end of the article

and multi-faceted. The development of test sets can lead
to inherent biases, such as selecting high-quality cases
only or selecting cases from unique clinical practices rather than random selection from large databases or populations [2-8]. To fully understand the strengths and
weaknesses of any study that utilizes test set methodology, the development of the test set must be fully described and reported. The GRRAS recommendations
provide a framework for doing so.
Most of the 15 GRRAS recommendations refer to the
presentation of study methods and interpretation of
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Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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results (Table 1). These include describing the diagnostic
or measurement device of interest, specifying the rater
population, and providing an in-depth description of the
sampling methods and sample size for both the subject
and rater populations.
In this paper, we use GRRAS recommendations to
provide an overview of our methods to create four diagnostic test sets for a study assessing agreement among
pathologists in the interpretation of breast biopsy specimens. The aims of the larger study include determining
relationships between characteristics of patients and pathologists and diagnostic accuracy of biopsy specimens.
In this paper, we focus on describing the sampling and
random assignment methods (GRRAS criteria 1–13,
Table 1) used to create the diagnostic test sets, as well as
the demographics of the patient subjects whose breast
biopsies were included in the test set cases. We also
identify and discuss important additional criteria that
would make GRRAS stronger and potentially even more
relevant when test sets are employed. The statistical
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analysis and results of the inter-rater agreement of the
test set cases will be reported elsewhere.

Methods and materials
IRB approval and consenting process

Biopsy specimens for the test set cases were identified
and obtained from the Breast Cancer Surveillance Consortium (BCSC) registries in Vermont and New Hampshire [9-11]. The BCSC is a collaborative network of five
geographically distinct mammography registries with
linkages to breast pathology and/or tumor registries
[10]. BCSC procedures are Health Insurance Portability
and Accountability Act (HIPAA) compliant and all registries have a Federal Certificate of Confidentiality and
other protection for the identities of research subjects
and the physicians and facilities that contribute data to
the BCSC [12]. Women enrolled in BCSC registries provided prior consent to BCSC investigators allowing their
archived tissue samples to be used for research [10].
Thus, the research subjects did not need to be re-

Table 1 Current GRRAS Guidelines and Suggested Additions to GRRAS
Current Guidelines for Reporting Reliability and
Agreement Studies (GRRAS) [1]
TITLE AND ABSTRACT

1. Identify in title or abstract that interrater/intrarater
reliability or agreement was investigated.

INTRODUCTION

2. Name and describe the diagnostic or measurement
device of interest explicitly.
3. Specify the subject population of interest.

Suggested Additions to GRRAS

Describe the database used to select the cases
and the quality of that data.

4. Specify the rater population of interest (if applicable).
5. Describe what is already known about reliability and
agreement and provide a rationale for the study
(if applicable).
METHODS

6. Explain how the sample size was chosen. State the
determined number of raters, subjects/objects, and
replicate observations.

Describe the sampling method and the underlying
population of both subjects and raters.
7. Define the Reference Standard diagnosis.

8. Describe the sampling method.
9. Describe the measurement/rating process (e.g. time
interval between repeated measurements, availability
of clinical information, blinding).
10. State whether measurements/ratings were conducted
independently.
11. Describe the statistical analysis.
RESULTS

12. State the actual number of raters and subjects/objects
which were included and the number of replicate observations
which were conducted.
13. Describe the sample characteristics of raters and subjects
(e.g. training, experience).
14. Report estimates of reliability and agreement including
measures of statistical uncertainty.

DISCUSSION

15. Discuss the practical relevance of results.

AUXILIARY MATERIAL

16. Provide detailed results if possible (e.g. online).
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consented for the development of the test sets created
for the current study.
Institutional Review Boards at the University of
Washington, Dartmouth College, the University of
Vermont, Fred Hutchinson Cancer Research Center,
and Providence Health & Services of Oregon approved
all test set study activities. A study-specific Certificate
of Confidentiality (NCI 11–049) was also obtained to
protect the study findings from forced disclosure of
identifiable information.
Test set case identification and selection

All biopsies used for the test set cases were performed
between January 1, 2000 and December 31, 2008. Only
excisional and core needle biopsies were used. Total
mastectomy cases and fine needle aspiration specimens
were excluded. Only one biopsy per woman was selected. When multiple biopsies were available from a
single woman we randomly selected a biopsy within a
hierarchical classification of cases with available clinical
history. We prioritized biopsies in which the woman’s
hormone therapy (HT) status at time of biopsy was
known. If HT status was unknown, cases were selected
by availability of information on family history. If both
HT and family history were unknown cases were selected by known race.
All women with a previous history of breast cancer
were excluded. A family history of breast cancer was defined as having a first degree relative (i.e., mother,
daughter or sister) with a breast cancer diagnosis. Breast
cancer history was assessed through a yes/no response
to the following questions, depending on the BCSC site,
on a risk factor questionnaire: “Have you ever been diagnosed with breast cancer?” or “Has the patient ever had
breast cancer?”. A total of 19,498 biopsies obtained from
13,677 distinct women met our eligibility requirements.
Test set cases were selected using random stratified
sampling based on the age of the woman (40–49 vs.
≥50), breast density (low vs. high), and the final diagnostic interpretation of the original BCSC contributing
pathologist who reviewed the woman’s biopsy for clinical
treatment and management. Contributing BCSC pathologists include a variety of practice settings ranging from
private practices in small hospitals to large Universityaffiliated academic practices in tertiary medical centers.
For all potential test set cases, we categorized the diagnostic interpretations of the BCSC pathologist into one
of five diagnostic classifications (non-proliferative changes,
proliferative changes without atypia, atypical ductal
hyperplasia (ADH), ductal carcinoma in situ (DCIS),
and invasive breast carcinoma). This resulted in 20 possible combinations of test set cases (5 diagnostic categories x 2 age groups x 2 breast density groups = 20
combinations). Low versus high breast density was
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defined as ≤ 50% fibroglandular (BI-RADS categories 1
and 2) or ≥ 51% fibroglandular (BI-RADS categories 3
and 4), respectively. Information on breast density was
obtained from mammography exams in the three years
prior to biopsy. We used data from the most proximal
mammogram for women with multiple mammograms
within the three year period.
We oversampled cases of ADH and DCIS compared
to national estimates of biopsy outcomes in the U.S. [13]
to increase statistical confidence and raw rates of interobserver variation in areas of breast pathology that may
be more challenging to interpret, are lower frequency
diagnoses, and where disagreements would affect treatment. Population-based adjustments according to disease prevalence will be made during statistical analysis.
Previous studies have shown misclassification rates
among pathologists of over 50% for ADH and 17% for
DCIS [14]. Women in their 40s and women with dense
breast tissue were also oversampled because age and
breast density are known risk factors for both benign
breast disease and breast cancer [15], and because our
a priori hypotheses include that there is more diagnostic variability in biopsies from women aged 40–49 years
and women with dense breast tissue. By design, half of
the test set cases were from women aged 40–49 at the
time of the biopsy and half were from women aged 50
and older, with no upper age limit. Also by design, half
of the cases were from women with high-density breast
tissue and half were from women with low-density
breast tissue.
A listing of candidate cases was randomly identified
from the Vermont and New Hampshire BCSC registries
(data not shown). Tissue blocks and original slides were
requested from clinical facilities in Vermont (n=8) and
New Hampshire (n=8) for review by our expert pathology panel. If a facility did not send the material after
three written requests and two phone requests, we removed that case from our selection and requested the
next case on the list within the 20 selection categories
until we met our target accrual of 425 cases (Figure 1).
Not all cases were available at the time of request. Reasons for a case being unavailable included insufficient residual tissue in paraffin blocks, the facility required
additional consent procedures, or the tissue had already
been discarded.
Initial review of biopsy material

An expert pathology panel comprised of three internationally recognized breast pathologists reviewed all selected
cases. One expert panel member conducted an initial assessment of all original slides associated with the biopsy
received from the clinical facility. The woman’s age and biopsy type (core needle or excisional) were the only clinical
history provided for each case. This expert was blinded to
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Breast tissue specimens available at Vermont and New Hampshire Breast
Cancer Surveillance Consortium (BCSC) registries for women aged > 40 years
who received a breast biopsy between January 1, 2000 - December 31, 2008.
N=19,498 from 13,677 distinct women.

Cases randomly selected for preliminary
review and available from clinical
facility
N=425

Case not included in study after
preliminary review, N=55
- Cases randomly removed because diagnostic, age or
density category full, n=25
- Not enough tissue present to interpret slide, n=24
- Tissue other than breast present, n=5
- Tissue block not available from clinical facility, n=1

Cases reviewed by expert pathology
panel using new study-specific slides
N= 370

Cases removed, N=34
- Case removed due to artifact on slide, n=16
- Cases randomly removed because diagnostic, age and
density category full, n=15
- Male breast tissue present, n=1
- Atypical lactation changes present, n=1
- Ineligible due to age <40 years at time of biopsy, n=1

Cases available for possible inclusion in final test set
N= 336

Cases randomly selected for final test set
N=240

Test Set A
N=60

Test Set B
N=60

Test Set C
N=60

Test Set D
N=60

Figure 1 Flow chart describing test set development.

the original diagnosis made by the contributing pathologist.
After the initial review was complete, new study-specific
glass slides were created from each case’s appropriate paraffin embedded tissue block(s) to ensure consistent staining
and image quality. The newly created slides were used for
the full expert panel review.
Standardized data collection

We developed a standardized histology data collection
form, called the Breast Pathology Assessment Tool Hierarchy (B-PATH) form, which the expert pathologists
used to record detailed diagnostic information about
each case during their review. The B-PATH form included the same five diagnostic categories that were used
for case selection (non-proliferative changes, proliferative changes without atypia, ADH, DCIS, and invasive

breast carcinoma). The expert pathologists were asked
to indicate if the case was borderline between two diagnostic categories and whether they would have requested
a second diagnostic opinion for the case had they seen it
in clinical practice. Finally, the B-PATH form asked pathologists to rate the level of diagnostic difficulty and
their level of confidence in the assessment of each case
using a 6-point Likert scale, with 1 representing “very
easy” or “very confident” and 6 representing “very challenging” or “not confident”, respectively.
Independent and consensus review by expert panel

The 3-member expert pathologist panel (including the expert who conducted the initial review of the original tissue
slides) performed blinded independent assessments on
each slide using the standardized B-PATH form.
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We used a modified Delphi approach [16] to establish
the final reference standard diagnosis for each slide. This
involved compiling the independent reviews for each
case, providing the three experts with their initial interpretation of the slides, followed by a facilitated discussion of features and diagnostic criteria of areas where
disagreement among the experts occurred during a rereview of the slide(s) at a multi-headed microscope. The
facilitated discussion continued until a final consensus
was reached among all three expert pathologists on the
case interpretation. When more than one slide was available for a case, the panel selected the slide that was most
representative of the diagnosis.
Sample size calculations and random assignment of cases
into four diagnostic test sets

The number of cases per test set and the number of participating study pathologists were chosen to provide sufficient power to address the study aims. Using conservative
assumptions about diagnostic variability among pathologists, [14] we determined that 60 cases per test set of glass
slides interpreted by 100 participating pathologists would,
for example, yield 90% power to detect an effect of patient
age (40–49 vs. ≥50 years) on a misclassification rate difference as small as 4.8% when interpreting cases with atypia
and DCIS.
After the three expert pathologists reached final diagnostic consensus, and each case had been mapped into
one of five primary diagnostic categories (Table 2), 240
unique patient cases were randomly selected from a total
of 336 cases reviewed by the expert panel (Figure 1). Selection was performed within cells defined by three
stratification factors in order to obtain the desired distribution of cases across factors. These included 1) case
diagnosis (using the five diagnostic categories on the B-
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PATH data collection form), 2) patient age (40–49 vs.
≥50), and 3) breast density (low vs. high), respectively. A
permuted block randomization method with block size
of four was used to assign cases to the four test sets.
Blocks were defined within strata by similarity of case
difficulty score (i.e., the mean Likert rating on the difficulty level assigned to each case by the three expert pathologists). For strata in which the cell total was not
evenly divisible by four, random permutations of the
relevant sets were assigned to the remaining partial
block. Four final test sets were developed, each of which
contained 60 unique patient cases.
We aimed to create a test set of slides that, as closely
as possible, mirrored the quality and variety of cases observed in everyday clinical practice. We recognize that
there is a wide range of diagnostic quality of source material; our statistical sampling and selection methods
were designed to eliminate or minimize selection bias.
Cases were deemed ineligible only when there was slide
preparation artifact or insufficient tissue present to interpret the slide (n=40), tissue other than breast tissue
was present on the slide due to a contributing facility
supplying an incorrect block (n=5), the tissue block was
unavailable (n=1), male breast tissue was present (n=1),
or atypical lactation changes were present (n=1). The
final set of eligible cases selected may not be considered
necessarily easy or difficult to interpret, or ideal for
teaching purposes because the selection process was
designed to circumvent the type of selection bias that
may exist in typical continuing medical educational
conferences and courses.
The results of the inter-rater agreement of the test sets
and a description of how the test sets will be used to assess agreement in pathologists’ diagnostic interpretation
of breast tissue will be reported elsewhere. In brief,

Table 2 Diagnostic Breast Pathology Assessment Tool Hierarchy (B-PATH) mapping categories for test set cases
Primary clinical diagnostic category
I. Non-Proliferative*

All diagnoses included in primary clinical diagnostic categories
Non-Proliferative only
Fibroadenoma

II. Proliferative changes without atypia

Usual ductal hyperplasia
Columnar cell hyperplasia/columnar cell changes
Sclerosing adenosis
Radial Scar/complex sclerosing lesion
Flat epithelial atypia
Intraductal papilloma w/o atypia

III. Atypical ductal hyperplasia (ADH)

Atypical ductal hyperplasia
Intraductal papilloma with atypia

IV. Ductal carcinoma in situ (DCIS)

Ductal carcinoma in situ

V. Invasive breast cancer

Invasive (ductal or lobular or other special type)

*For development of the test set, cases were categorized according to the highest ductal proliferative or malignant lesion present on the slide. When only lobular
carcinoma in situ (LCIS) or atypical lobular hyperplasia (ALH) was present (n=2), we categorized cases as non-proliferative.
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approximately 200 study pathologists will be invited to
independently review the test set cases and provide their
diagnostic interpretation. These interpretations will be
compared to the reference standard diagnoses as determined by the expert pathology panel and to the interpretations of other pathologists in the study.

Discussion
In this paper we provide an example of how GRRAS recommendations can be applied to developing and reporting
the methods used to create diagnostic test sets to assess
interpretive reliability and diagnostic agreement. Previous
studies have described the poor quality of research
reporting [17-19] but, encouragingly, research has also
shown that the development and use of formalized guidelines improves the quality of reporting [20]. The methods
that are used to develop test sets contribute importantly
to the validity of study findings. Thus, providing a clear
description of methodological details and standardized
terminology [21] is critical in assisting readers to assess
the strengths and shortcomings of the study findings,
especially as they relate to implications for clinical care.
Because the GRRAS recommendations are new, Kottner
et al. [1] invited researchers to provide feedback on
whether use of the guidelines improves reporting for studies of reliability and agreement, and to suggest updates for
the guidelines themselves. Our investigative team found
GRRAS very helpful in describing the complex methods
of developing a diagnostic breast pathology test set. In
addition to the current GRRAS recommendations, we
suggest the inclusion of additional guidelines for test set
development that may be applicable to other studies. First,
we suggest that data sources for patient populations be
well characterized, both in terms of geographic and health
system features. This is important because if patients are
from a small geographic area (e.g., a single clinic or hospital) they will likely be different from those identified
from a large geographic sample or dataset and as such will
affect the generalizability of the study results. Second, if
accuracy is being investigated, researchers should describe
the methods used to define the reference diagnosis or gold
standard. The importance of documenting this is widely
recognized in guidelines for reporting diagnostic accuracy
studies such as STARD [22]. While some studies of interrater reliability are designed to evaluate agreement, it is
often more clinically useful to understand accuracy. Studies can be designed using external tests or additional clinical follow-up to define a reference standard diagnosis. For
example, two years of follow-up can be used to determine
if breast cancer develops in studies of variability of radiologists’ interpretation of mammography, [23] and echocardiography can be used as the reference standard to assess
the diagnostic accuracy of physicians identifying cardiac
lesion type and severity by auscultation [24].
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Breast cancer diagnosis and treatment relies on pathologists’ interpretation of breast biopsy specimens. However,
studies investigating levels of interpretive agreement when
diagnosing breast cancer and precursor lesions are limited
[8,14]. The substantial clinical disagreement in pathological interpretation of borderline cases raises concern
about over or under treatment of women with precursor
lesions such as ADH and DCIS. In addition, misclassifications alter the study of patient outcomes associated with
effective treatment. The use of carefully developed test
sets provides an opportunity to improve our understanding of interpretive variation and its underlying causes.
Strengths and limitations

Studies of observer reliability and accuracy often rely on
test sets. Yet, the use of test sets, no matter how carefully developed, opens the door to limitations shared by
these studies, including ours. First, the use of test sets
may cause clinicians to modify their opinion to reflect
what they believe is the “right” response [25,26]. Second,
performance on test sets may not reflect performance in
clinical practice [25,27]. An ideal study design might include embedding test cases into actual clinical practice
while keeping the interpreting clinician blinded to test
cases. However, it is logistically impractical to keep pathologists blinded to test cases in studies that involve
large numbers of physicians from multiple geographic
locations and a large number of test cases. Third, as described by Kundel et al. [28] accuracy in many studies
is only implied with the assumption that when readers
agree they must be correct. However, readers may all
agree and also be wrong. There is not a perfect method
to define a reference standard, but studies have found
that the use of consensus ratings by experts show more
accurate estimates of case diagnosis and outcomes
compared to non-consensus trials, even when raters’
bias is considered [29]. By requiring complete consensus of our experts on their diagnostic interpretation of
all of our test set cases, we expect to achieve the most
rigorous reference diagnosis possible for each test set
case in this study.
Our meticulously developed test set used a random
case selection process within specific diagnostic categories and had a large sample size, allowing our study design to modify some of the problems inherent in
previously reported observer variability studies. Test sets
are typically selected with a focus on difficult cases, narrowly selected diagnoses or cases handpicked for unique
attributes or high quality. By contrast, our randomly selected test set excluded cases only when there was insufficient diagnostic tissue on the slide or incorrect source
tissue blocks were supplied. For this reason, the test sets
included cases that some clinicians might interpret as
having borderline diagnoses and cases that may not
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typically be considered ideal for a teaching or training
set, but that more accurately reflect the real-world
spectrum of findings within each diagnostic category.
A unique strength of our study is that the case selection methods will allow us to eventually combine our
test set interpretive findings with data on the diagnostic
distributions of breast biopsy cases from all National
Cancer Institute BCSC sites, which are representative of
the U.S. population [10,30]. Because the study cases
oversampled ADH and DCIS cases we will carefully
model the data taking into consideration the prevalence
of each diagnostic category in the U.S., based on previously published BCSC data [13] and new data that we
are collecting from the BCSC. Study findings will be
combined with other U.S. data to provide population estimates on the impact that alternative breast pathology
reading practices may have on health and resource use
among women undergoing breast biopsies.

Conclusions
The use of test sets is a valuable research tool that contributes importantly to the reliability and face validity in
studies on agreement in diagnosis of biopsy specimens.
The methods used to develop these test sets, however,
are complex and multi-faceted and contribute to the accuracy of study results. The intent of GRRAS is to provide a framework to fully describe the methods by which
a score, rating, or measurement has been determined [1]
so that practitioners and researchers alike can weigh this
information along with the study findings. Formalized
guidance in reporting is welcomed by many researchers,
and the use of guidelines has been found to improve the
reporting of research results. We found GRRAS recommendations to be helpful, and encourage their use along
with our suggested additions to GRRAS, characterizing
the study population and describing the methods used
to define the reference diagnosis, when applicable.
Competing interests
In the past five years none of the authors have received reimbursements,
fees, funding, or salary from an organization that may in any way gain or
lose financially from the publication of this manuscript, either now or in the
future. No financial organizations are financing this manuscript (including the
article-processing charge). No authors hold stocks or shares in an
organization that may in any way gain or lose financially from the
publication of this manuscript, either now or in the future. None of the
authors hold or are currently applying for any patents relating to the content
of the manuscript. We have not received reimbursements, fees, funding, or
salary from an organization that holds or has applied for patents relating to
the content of the manuscript. We have no other financial competing
interests to disclose. None of the authors have non-financial competing
interests (political, personal, religious, ideological, academic, intellectual,
commercial or any other) to declare in relation to this manuscript.
Authors’ contributions
NVO: Participated in study design and implementation. Drafted manuscript.
PAC: A key participant in the study design and manuscript preparation.
Developed and facilitated the modified Delphi method during the expert
panel’s consensus meetings which were used to determine the reference

Page 7 of 8

standard consensus diagnosis for test set cases. KHA: Participated in study
design and conception. Edited manuscript. Key participant in diagnostic
agreement discussions during expert consensus meetings. DLW: Key
participant in expert consensus meeting and overall study design. Edited
manuscript. LR: Participated in the study design and implementation.
Facilitated diagnostic consensus meetings. Participated in drafting of
manuscript. GL: Performed sample size calculations, performed random
statistical assignment of all biopsy cases into four diagnostic test sets and
provided oversight on statistical issues during development of the test set.
TO: Participated in design of the study, manuscript preparation and editing.
MP: Key participant in the statistical design of the study. Provided oversight
on statistical analysis during study development and implementation. BMG:
Participated in study design and conception. Co-facilitated the modified
Delphi method during the expert panel’s consensus meetings. Edited
manuscript. HN: Study design and conception, manuscript preparation. TR:
Performed statistical analysis to identify and select test set cases from the
BCSC. AT: Key participant in study conception and design. JGE: Overall study
design, conception and implementation. Key participant in manuscript
writing and editing. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by the National Cancer Institute (R01 CA140560)
and by the National Cancer Institute-funded Breast Cancer Surveillance
Consortium (U01CA86082, U01CA70013, U01CA69976, HHSN261201100031C).
The content is solely the responsibility of the authors and does not
necessarily represent the views of the National Cancer Institute or the
National Institutes of Health. The collection of cancer and vital status data
used in this study was supported in part by several state public health
departments and cancer registries throughout the U.S. For a full description
of these sources, please see: http://www.breastscreening.cancer.gov/work/
acknowledgement.html. The authors sincerely thank Sara Jackson, MD at the
University of Washington for her review of this manuscript. We also
gratefully acknowledge Tom Morgan at the University of Washington for his
role in the project management of this study.
Author details
1
Department of Medicine, University of Washington, Seattle, WA, USA.
2
Department of Family Medicine, Oregon Health and Science University,
Portland, OR, USA. 3Department of Pathology, Stanford University School of
Medicine, Palo Alto, CA, USA. 4Department of Pathology, University of
Vermont and Vermont Cancer Center, Burlington, VT, USA. 5Public Health
Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
6
Norris Cotton Cancer Center and The Dartmouth Institute for Health Policy
and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, NH,
USA. 7Office of Health Promotion Research, University of Vermont,
Burlington, VT, USA. 8Department of Medical Informatics and Clinical
Epidemiology, Oregon Health and Science University, Portland, OR, USA.
Received: 1 October 2012 Accepted: 18 January 2013
Published: 5 February 2013
References
1. Kottner J, Audige L, Brorson S, Donner A, Gajewski BJ, Hrobjartsson A,
Roberts C, Shoukri M, Streiner DL: Guidelines for reporting reliability and
agreement studies (GRRAS) were proposed. J Clin Epidemiol 2011,
64(1):96–106.
2. Schnitt SJ, Connolly JL, Tavassoli FA, Fechner RE, Kempson RL, Gelman R,
Page DL: Interobserver reproducibility in the diagnosis of ductal
proliferative breast lesions using standardized criteria. Am J Surg Pathol
1992, 16(12):1133–1143.
3. Rosai J: Borderline epithelial lesions of the breast. Am J Surg Pathol 1991,
15(3):209–221.
4. Petralia G, Bonello L, Summers P, Preda L, Malasevschi A, Raimondi S, Di
Filippi R, Locatelli M, Curigliano G, Renne G, et al: Intraobserver and
interobserver variability in the calculation of apparent diffusion
coefficient (ADC) from diffusion-weighted magnetic resonance imaging
(DW-MRI) of breast tumours. Radiol Med 2011, 116(3):466–476.
5. Imamura T, Isomoto I, Sueyoshi E, Yano H, Uga T, Abe K, Hayashi T,
Honda S, Yamaguchi T, Uetani M: Diagnostic performance of ADC for
Non-mass-like breast lesions on MR imaging. Magn Reson Med Sci
2010, 9(4):217–225.

Oster et al. BMC Women's Health 2013, 13:3
http://www.biomedcentral.com/1472-6874/13/3

6.

7.
8.

9.

10.
11.

12.

13.

14.

15.
16.

17.

18.
19.

20.

21.

22.

23.

24.

25.
26.
27.

28.

Darvishian F, Singh B, Simsir A, Ye W, Cangiarella JF: Atypia on breast core
needle biopsies: reproducibility and significance. Ann Clin Lab Sci 2009,
39(3):270–276.
Haupt B, Schwartz MR, Xu Q, Ro JY: Columnar cell lesions: a consensus
study among pathology trainees. Hum Pathol 2010, 41(6):895–901.
Wells WA, Carney PA, Eliassen MS, Tosteson AN, Greenberg ER: Statewide
study of diagnostic agreement in breast pathology. JNCI 1998,
90(2):142–145.
Weaver DL, Vacek PM, Skelly JM, Geller BM: Predicting biopsy outcome
after mammography: what is the likelihood the patient has invasive or
in situ breast cancer? Ann Surg Oncol 2005, 12(8):660–673.
Breast cancer surveillance consortium. 2011. Available at: http://
breastscreening.cancer.gov. Accessed June 1, 2011.
Carney PA, Poplack SP, Wells WA, Littenberg B: The New hampshire
mammography network: the development and design of a populationbased registry. Am J Roentgenol 1996, 167(2):367–372.
Carney PA, Geller BM, Moffett H, Ganger M, Sewell M, Barlow WE, Stalnaker
N, Taplin SH, Sisk C, Ernster VL, et al: Current medicolegal and
confidentiality issues in large, multicenter research programs. Am J
Epidemiol 2000, 152(4):371–378.
Weaver DL, Rosenberg RD, Barlow WE, Ichikawa L, Carney PA, Kerlikowske K,
Buist DS, Geller BM, Key CR, Maygarden SJ, et al: Pathologic findings from
the breast cancer surveillance consortium: population-based outcomes
in women undergoing biopsy after screening mammography. Cancer
2006, 106(4):732–742.
Collins LC, Connolly JL, Page DL, Goulart RA, Pisano ED, Fajardo LL, Berg
WA, Caudry DJ, McNeil BJ, Schnitt SJ: Diagnostic agreement in the
evaluation of image-guided breast core needle biopsies: results from a
randomized clinical trial. Amer J Surg Path 2004, 28(1):126–131.
Ginsburg OM, Martin LJ, Boyd NF: Mammographic density, lobular
involution, and risk of breast cancer. Brit J Cancer 2008, 99(9):1369–1374.
Helmer-Hirschberg O: The systematic Use of expert judgment in operations
research. Available at: http://www.rand.org/pubs/papers/P2795.html.
Accessed August, 2012.
Pocock SJ, Collier TJ, Dandreo KJ, de Stavola BL, Goldman MB, Kalish LA,
Kasten LE, McCormack VA: Issues in the reporting of epidemiological
studies: a survey of recent practice. BMJ 2004, 329(7471):883.
Honest H, Khan KS: Reporting of measures of accuracy in systematic
reviews of diagnostic literature. BMC Health Serv Res 2002, 2:4.
Smidt N, Rutjes AW, van der Windt DA, Ostelo RW, Reitsma JB, Bossuyt PM,
Bouter LM, de Vet HC: Quality of reporting of diagnostic accuracy studies.
Radiology 2005, 235(2):347–353.
Smidt N, Rutjes AW, van der Windt DA, Ostelo RW, Bossuyt PM, Reitsma JB,
Bouter LM, de Vet HC: The quality of diagnostic accuracy studies since
the STARD statement: has it improved? Neurology 2006, 67(5):792–797.
National Health Service Breast Screening Programme: Quality assurance
guidelines for breast pathology services. 2nd edition. 2011. Available at: http://
www.cancerscreening.nhs.uk/breastscreen/publications/nhsbsp02.pdf.
Accessed December 2012.
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM,
Moher D, Rennie D, de Vet HC, Lijmer JG: The STARD statement for
reporting studies of diagnostic accuracy: explanation and elaboration.
Ann Intern Med 2003, 138(1):W1–W12.
Elmore JG, Wells CK, Lee CH, Howard DH, Feinstein AR: Variability in
radiologists’ interpretations of mammograms. N Engl J Med 1994,
331(22):1493–1499.
Sztajzel JM, Picard-Kossovsky M, Lerch R, Vuille C, Sarasin FP: Accuracy of
cardiac auscultation in the era of doppler-echocardiography: a
comparison between cardiologists and internists. Int J Cardiol 2010,
138(3):308–310.
Egglin TK, Feinstein AR: Context bias. A problem in diagnostic radiology.
JAMA 1996, 276(21):1752–1755.
Bankier AA, Levine D, Halpern EF, Kressel HY: Consensus interpretation in
imaging research: is there a better way? Radiology 2010, 257(1):14–17.
Gur D, Bandos AI, Cohen CS, Hakim CM, Hardesty LA, Ganott MA, Perrin
RL, Poller WR, Shah R, Sumkin JH, et al: The “laboratory” effect:
comparing radiologists’ performance and variability during
prospective clinical and laboratory mammography interpretations.
Radiology 2008, 249(1):47–53.
Kundel HL, Polansky M: Measurement of observer agreement. Radiology
2003, 228(2):303–308.

Page 8 of 8

29. Weller SC, Mann NC: Assessing rater performance without a “gold
standard” using consensus theory. Med Decis Making 1997, 17(1):71–79.
30. Ballard-Barbash R, Taplin SH, Yankaskas BC, Ernster VL, Rosenberg RD, Carney
PA, Barlow WE, Geller BM, Kerlikowske K, Edwards BK, et al: Breast cancer
surveillance consortium: a national mammography screening and
outcomes database. Am J Roentgenol 1997, 169(4):1001–1008.
doi:10.1186/1472-6874-13-3
Cite this article as: Oster et al.: Development of a diagnostic test set to
assess agreement in breast pathology: practical application of the
Guidelines for Reporting Reliability and Agreement Studies (GRRAS).
BMC Women's Health 2013 13:3.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

